Phase II study of carboplatin as a single drug for relapsed Wilms' tumor: experience of the Brazilian Wilms' Tumor Study Group.
A total of 15 patients with relapsed Wilms' tumor were treated with carboplatin as a single agent. There were six females and nine males, aged between 2 and 9 years (median:5). The treatment consisted of carboplatin given I.V. as a single agent at a dose of 550 mg/m2 over 1 hour every 3 weeks. There were four (26%) complete responses, four (26%) partial responses, one stable disease, and six with progressive disease. In all patients a total of 56 courses were given and the toxicities found were leukopenia and thrombocytopenia. The overall response rate was encouraging and the toxicity was acceptable and reversible.
de Camargo
B
B
Department of Pediatrics, Hospital A.C. Camargo, São Paulo, Brazil.
Melaragno
R
R
Saba e Silva
N
N
Mendonça
N
N
Alvares
M N
MN
Morinaka
E
E
Marques
A
A
Cusato
M P
MP
D000008:Abdominal Neoplasms / Q000188:drug therapy / Q000556:secondary; D001938:Brazil; D016190:Carboplatin / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D012074:Remission Induction; D009396:Wilms Tumor / Q000188:drug therapy* / Q000556:secondary
D016190:Carboplatin